XENIOS is the therapy and technology leader in minimally invasive lung and heart assist. XENIOS’ novalung iLA, i–cor, and medos devices provide pulmonary and cardiac assist for a broad range of support levels on the unique XENIOS platform. XENIOS’ novalung iLA therapy is an adjunct or an alternative to injurious, immobilizing mechanical ventilation. XENIOS i-cor therapy is a novel heart assist therapy synchronized with the human heartbeat. These therapies enable caregivers to keep lung failure patients awake, self-determined and mobile while preventing ventilator-associated lung injury, pneumonia, and breathing muscle damage.
 
For watching our Xenios image video, please follow this link.

Events

46. Internationalen Jahrestagung der DGfK

Wed, 6 Sep 2017 - Sun, 26 Nov 2017


Unesco-Platz 1
Weimar, Thüringen 99423
Germany
 DIVI 2017

Wed, 6 Dec 2017 - Fri, 8 Dec 2017


Messeallee 1
Leipzig, 04158
Germany

News

ICU Management

Six Days Without a Lung – a Look into the Future of Medical Technology

2017 12 Apr

The dramatic story of Canadian Melissa Benoit, who lived for six days without a lung, shows a view of a new chapter in the history of medical technology. The novalung iLA membrane lung, which replaced the functions of the lung, is a product of XENIOS AG. As a strategic partner of XOR Labs in Toronto, both companies wanted to cooperate to revolutionize... Read more

Jobs not available

Catalogue

    Catalogue not available

Im Zukunftspark, 1
Heilbronn
74076
Germany
+49 7131 2706 422

White Papers - Case Studies

Not available

Videos

  • The future of extracorporeal lung support, I-I-I Interview with Dr. Georg Matheis, Novalung from HealthManagement.org on Vimeo.

Articles

Not available


Lung failure therapies

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD.

iLA activve Kits

Uncomplicated initiation of therapy and rapid exchange of the Membrane Ventilator kit if necessary.
There are 4 different sizes available:
· iLA activve MiniLung petite Kit
· iLA activve MiniLung Kit
· iLA activve iLA Kit
· iLA activve XLung Kit
With long-term approval for 29 days of use!
It’s all here – iLA activve Kits

· Optimized blood tubing with integrated iLA activve pump head and Luer Lock ports for pressure sensors – preconnected to the Membrane Ventilator.
· Additional accessories, including filling line, gas line, Christmas-tree connector and clamps.
· iLA Membrane Ventilator- The world’s only pumpless extrapulmonary gas exchange system


Medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using medos products. Upon the acquisition of Medos by novalung's owners the Medos blood pump technology allowed to create both iLA activve and i-cor synchronized cardiac assist for Xenios' state-of-the-art minimally invasive therapy portfolio.





Synchronized Cardiac Assist closes the gap between physiology and mechanical circulatory support

Although significant technical advances of extracorporeal life support (ECLS) systems have been made, the morbidity and mortality rates in patients requiring ECLS are still high, thus there is still a need for effective mechanical cardiac assist.

The novel i-cor Synchronized Cardiac Assist is a small extracorporeal pump that is synchronized to the heart beat (the ECG) so that augmentation of cardiac output with well-oxygenated blood occurs during diastole and does not represent an increased afterload on the heart during systole.

The technology designed to offer physiological circulatory support is expected to increase cardiac output, stabilize the vital signs and reduce the manifestations of cardiogenic shock.

In those patients receiving i-cor Synchronized Cardiac Assist during high risk PCI procedures, it is expected that myocardial tissue will be preserved and cardiac function protected by the device.

The anticipated benefits of using the i-cor device include the advantage of pulsatile perfusion in terms of surplus hemodynamic energy, achievable at lower mean flow and improved coronary perfusion.


Xenios:

Novalung: